: This Center for Cancer Nanotechnology Excellence focused on therapy response (CCNE-TR) brings together scientists and physicians from Stanford University, University of California Los Angeles (UCLA), Cedars Sinai Medical Center, Fredrick Hutchinson Cancer Center, University of Texas at Austin, Intel? Corporation, and General Electric Global Research in a novel proposal to utilize nanotechnology for the? benefit of cancer patient management. This research proposal is centered around our vision that ex vivo? diagnostics used in conjunction with in vivo diagnostics can markedly impact future cancer patient? management. Furthermore, we believe that nanotechnoloqy can significantly advance both ex vivo? diagnostics through proteomic nanosensors and in vivo diagnostics through nanoparticles for molecular? imaging. The cancer-related biochemical pathways targeted will be the Her-kinase axis with prostate cancer? as the initial focus, and CD20/c-myc with lymphoma as the second initial major focus. We have assembled a? highly interdisciplinary team of scientists from the fields of chemistry, materials science and engineering,? molecular imaging, oncology, cancer biology, protein engineering, biostatistics, and mathematical modeling? in order to accomplish our goals. We highly leverage resources at the Stanford Bio-X Program, National? Nanotechnology Infrastructure Network, the California Nanosystems Institute, the Stanford/UCLA/Fred Hutchinson? Cancer Centers, as well as significant resources with our two primary industrial partners (GE and Intel). We? also have direct links to a UCLA Prostate SPORE, the ICMIC P50 and ICBP P20 at Stanford as well as? several other NCI sponsored efforts. Furthermore, we have many methods for outreach and dissemination? including the Prostate Cancer Foundation (formerly named CaPCure) as well as the Canary Foundation.? Projects will focus on the use of magnetonanotechnology and nanotube/nanowire technology for ex vivo protein detection; the use of Raman sensors for protein phosphorylation detection; methods to determine? protein profiles on the cell surface, the secretome, and serum from mouse models and humans; the use of biologically targeted quantum dots for molecular imaging of living subjects; and mouse models for integrating ex vivo tissue/serum protein patterns and in vivo molecular imaging to predict response to anti-cancer therapy. Cores provide a nanocharacterization laboratory resource; service for fabricated nanostructures; and an informatics and biostatistics resource. Together, these highly interactive and cohesive programs will produce breakthroughs towards our vision of developing and validating nanotechnology for anti-cancer therapy response.?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA119367-02
Application #
7231636
Study Section
Special Emphasis Panel (ZCA1-GRB-S (O1))
Program Officer
Grodzinski, Piotr
Project Start
2006-05-12
Project End
2011-04-30
Budget Start
2007-08-14
Budget End
2008-04-30
Support Year
2
Fiscal Year
2007
Total Cost
$3,756,608
Indirect Cost
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Shah, Preyas N; Lin, Tiras Y; Aanei, Ioana L et al. (2018) Extravasation of Brownian Spheroidal Nanoparticles through Vascular Pores. Biophys J 115:1103-1115
Kani, Kian; Garri, Carolina; Tiemann, Katrin et al. (2017) JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Mol Cancer Ther 16:1645-1657
Antaris, Alexander L; Chen, Hao; Diao, Shuo et al. (2017) A high quantum yield molecule-protein complex fluorophore for near-infrared II imaging. Nat Commun 8:15269
Smith, Bryan Ronain; Gambhir, Sanjiv Sam (2017) Nanomaterials for In Vivo Imaging. Chem Rev 117:901-986
Shou, Kangquan; Qu, Chunrong; Sun, Yao et al. (2017) Multifunctional biomedical imaging in physiological and pathological conditions using a NIR-II probe. Adv Funct Mater 27:
Feng, Yi; Zhu, Shoujun; Antaris, Alexander L et al. (2017) Live imaging of follicle stimulating hormone receptors in gonads and bones using near infrared II fluorophore. Chem Sci 8:3703-3711
Willmann, Jürgen K; Bonomo, Lorenzo; Carla Testa, Antonia et al. (2017) Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results. J Clin Oncol 35:2133-2140
Antaris, Alexander L; Chen, Hao; Cheng, Kai et al. (2016) A small-molecule dye for NIR-II imaging. Nat Mater 15:235-42
Pu, Kanyi; Chattopadhyay, Niladri; Rao, Jianghong (2016) Recent advances of semiconducting polymer nanoparticles in in vivo molecular imaging. J Control Release 240:312-322
Zhang, Ruiping; Cheng, Kai; Antaris, Alexander L et al. (2016) Hybrid anisotropic nanostructures for dual-modal cancer imaging and image-guided chemo-thermo therapies. Biomaterials 103:265-277

Showing the most recent 10 out of 228 publications